We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$70.5M
AUM Growth
–
Cap. Flow
+$69.7M
Cap. Flow %
98.82%
Top 10 Hldgs %
77.88%
Holding
45
New
45
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$10.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$9.65M
3
CELG
Celgene Corp
CELG
+$9.26M
4
MRK icon
Merck
MRK
+$5.5M
5
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$3.98M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
1
Pfizer
PFE
$141B
$10.7M 15.11%
+347,820
New +$10.9M
BMY icon
2
Bristol-Myers Squibb
BMY
$123B
$10M 14.25%
+146,000
New +$9.65M
CELG
3
DELISTED
Celgene Corp
CELG
$9.58M 13.59%
+80,000
New +$9.26M
MRK icon
4
Merck
MRK
$307B
$5.49M 7.79%
+108,992
New +$5.5M
SGEN
5
DELISTED
Seagen Inc. Common Stock
SGEN
$4.04M 5.73%
+90,000
New +$3.75M
ABBV icon
6
AbbVie
ABBV
$448B
$3.64M 5.17%
+61,500
New +$3.54M
CNCE
7
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$3.47M 4.93%
+183,000
New +$3.98M
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.12M 4.43%
+144,000
New +$2.8M
AGN
9
DELISTED
Allergan plc
AGN
$2.88M 4.08%
+9,200
New +$2.74M
ALDR
10
DELISTED
Alder Biopharmaceuticals
ALDR
$1.98M 2.81%
+60,000
New +$2.03M
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.4B
$1.53M 2.17%
+27,000
New +$1.37M
IOVA icon
12
Iovance Biotherapeutics
IOVA
$2.24B
$1.18M 1.67%
+152,266
New +$1.06M
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$892K 1.27%
+21,500
New +$721K
NDRM
14
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$818K 1.16%
+48,000
New +$935K
CTIC
15
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$807K 1.14%
+65,600
New +$876K
IMDZ
16
DELISTED
Immune Design Corp.
IMDZ
$803K 1.14%
+40,000
New +$689K
AERI
17
DELISTED
Aerie Pharmaceuticals
AERI
$688K 0.98%
+28,240
New +$659K
HRTX icon
18
Heron Therapeutics
HRTX
$90.9M
$630K 0.89%
+23,600
New +$631K
DRRX
19
DELISTED
DURECT Corp
DRRX
$622K 0.88%
+28,151
New +$609K
SCLN
20
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$598K 0.85%
+65,000
New +$544K
QURE icon
21
uniQure
QURE
$2.73B
$595K 0.84%
+36,000
New +$667K
ADXS
22
DELISTED
Advaxis Inc
ADXS
$556K 0.79%
+3,684
New +$633K
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$375M
$476K 0.68%
+10,500
New +$458K
CASC
24
DELISTED
Cascadian Therapeutics, Inc.
CASC
$444K 0.63%
+33,333
New +$574K
INO icon
25
Inovio Pharmaceuticals
INO
$89.7M
$403K 0.57%
+5,000
New +$398K
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Nexthera Capital, which disclosed 45 positions worth $70.5M. Its ten largest holdings account for 78% of the portfolio.

Its largest position is Pfizer: 347,820 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets.

  • Nexthera Capital's largest Q4 2015 buy was Pfizer: 347,820 shares worth $10.7M.
  • Nexthera Capital's ten largest holdings make up 78% of its $70.5M portfolio in Q4 2015.
  • Nexthera Capital disclosed 45 positions in Q4 2015, its first 13F filing on record.

Based on Nexthera Capital's 13F filing for Q4 2015, filed 16 Feb 2016.